Regeneron Pharmaceuticals Inc
REGN784.970USD
+1.260+0.16%
終値 12/26, 16:00（ET）15分遅れの株価
82.66B時価総額
18.10直近12ヶ月PER
詳細情報 Regeneron Pharmaceuticals Inc 企業名
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Regeneron Pharmaceuticals Incの企業情報
企業コードREGN
会社名Regeneron Pharmaceuticals Inc
上場日Apr 02, 1991
最高経営責任者「CEO」Schleifer (Leonard S)
従業員数15106
証券種類Ordinary Share
決算期末Apr 02
本社所在地777 Old Saw Mill River Road
都市TARRYTOWN
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号10591
電話番号17813705000
ウェブサイトhttps://www.regeneron.com/
企業コードREGN
上場日Apr 02, 1991
最高経営責任者「CEO」Schleifer (Leonard S)
Regeneron Pharmaceuticals Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
56.41K
+3.71%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
44.85K
+2.47%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
37.73K
+5.04%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
21.78K
+10.31%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.66K
-0.10%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
15.51K
+7.93%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.62K
-0.13%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
56.41K
+3.71%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
44.85K
+2.47%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
37.73K
+5.04%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Sanofi
1.44B
39.28%
EYLEA
754.30M
20.52%
Bayer
415.00M
11.29%
EYLEA HD
393.20M
10.70%
Libtayo
247.80M
6.74%
他の
421.70M
11.47%
会社から関連データがまだ開示されていません。
事業別
地域別
事業別USD
会社名
収益
比率
Sanofi
1.44B
39.28%
EYLEA
754.30M
20.52%
Bayer
415.00M
11.29%
EYLEA HD
393.20M
10.70%
Libtayo
247.80M
6.74%
他の
421.70M
11.47%
株主
更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
8.71%
BlackRock Institutional Trust Company, N.A.
5.29%
State Street Investment Management (US)
4.54%
Dodge & Cox
4.41%
JP Morgan Asset Management
2.85%
他の
74.20%
株主統計
株主統計
比率
The Vanguard Group, Inc.
8.71%
BlackRock Institutional Trust Company, N.A.
5.29%
State Street Investment Management (US)
4.54%
Dodge & Cox
4.41%
JP Morgan Asset Management
2.85%
他の
74.20%
種類
株主統計
比率
Investment Advisor
45.12%
Investment Advisor/Hedge Fund
30.91%
Hedge Fund
5.04%
Pension Fund
2.69%
Research Firm
2.61%
Bank and Trust
2.25%
Individual Investor
2.06%
Sovereign Wealth Fund
1.23%
Insurance Company
0.20%
他の
7.89%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
2596
94.26M
91.26%
-4.21M
2025Q2
2585
99.72M
95.69%
-2.03M
2025Q1
2621
99.84M
93.97%
-1.42M
2024Q4
2581
100.17M
93.15%
-475.65K
2024Q3
2505
99.81M
90.67%
-1.99M
2024Q2
2479
100.87M
93.10%
+570.24K
2024Q1
2440
99.77M
92.44%
+388.23K
2023Q4
2406
98.50M
91.94%
-617.06K
2023Q3
2358
98.79M
92.52%
-1.71M
2023Q2
2360
99.25M
92.00%
-1.42M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
9.37M
9%
+14.55K
+0.16%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.67M
5.44%
-75.61K
-1.32%
Jun 30, 2025
State Street Investment Management (US)
4.83M
4.64%
+42.34K
+0.88%
Jun 30, 2025
Dodge & Cox
3.83M
3.67%
+1.50M
+64.64%
Jun 30, 2025
JP Morgan Asset Management
2.82M
2.7%
-1.26M
-30.95%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.47M
2.37%
-4.53K
-0.18%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
2.17M
2.09%
-7.70K
-0.35%
Aug 31, 2025
Putnam Investment Management, L.L.C.
2.03M
1.95%
+116.30K
+6.08%
Jun 30, 2025
Capital World Investors
1.97M
1.89%
+27.38K
+1.41%
Jun 30, 2025
Loomis, Sayles & Company, L.P.
1.94M
1.86%
+305.09K
+18.65%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
ProShares Ultra Nasdaq Biotechnology
6.6%
Invesco Nasdaq Biotechnology ETF
6.55%
Amplify Weight Loss Drug & Treatment ETF
6.4%
iShares Biotechnology ETF
5.9%
Simplify Health Care ETF
5.54%
VanEck Biotech ETF
5.51%
Invesco Biotechnology & Genome ETF
5.4%
iShares Genomics Immunology and Healthcare ETF
4.97%
First Trust NASDAQ Pharmaceuticals ETF
4.36%
First Trust NYSE Arca Biotechnology Index Fund
3.88%
詳細を見る
ProShares Ultra Nasdaq Biotechnology
比率6.6%
Invesco Nasdaq Biotechnology ETF
比率6.55%
Amplify Weight Loss Drug & Treatment ETF
比率6.4%
iShares Biotechnology ETF
比率5.9%
Simplify Health Care ETF
比率5.54%
VanEck Biotech ETF
比率5.51%
Invesco Biotechnology & Genome ETF
比率5.4%
iShares Genomics Immunology and Healthcare ETF
比率4.97%
First Trust NASDAQ Pharmaceuticals ETF
比率4.36%
First Trust NYSE Arca Biotechnology Index Fund
比率3.88%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
Feb 04, 2025
REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025
Feb 20, 2025
Mar 20, 2025
Feb 20, 2025
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
Regeneron Pharmaceuticals Incの上位5名の株主は誰ですか？
Regeneron Pharmaceuticals Incの上位5名の株主は以下のとおりです。
The Vanguard Group, Inc.は9.37M株を保有しており、これは全体の9.00%に相当します。
BlackRock Institutional Trust Company, N.A.は5.67M株を保有しており、これは全体の5.44%に相当します。
State Street Investment Management (US)は4.83M株を保有しており、これは全体の4.64%に相当します。
Dodge & Coxは3.83M株を保有しており、これは全体の3.67%に相当します。
JP Morgan Asset Managementは2.82M株を保有しており、これは全体の2.70%に相当します。
The Vanguard Group, Inc.は9.37M株を保有しており、これは全体の9.00%に相当します。
BlackRock Institutional Trust Company, N.A.は5.67M株を保有しており、これは全体の5.44%に相当します。
State Street Investment Management (US)は4.83M株を保有しており、これは全体の4.64%に相当します。
Dodge & Coxは3.83M株を保有しており、これは全体の3.67%に相当します。
JP Morgan Asset Managementは2.82M株を保有しており、これは全体の2.70%に相当します。
Regeneron Pharmaceuticals Incの株主タイプ上位3種は何ですか？
Regeneron Pharmaceuticals Incの株主タイプ上位3種は、
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Regeneron Pharmaceuticals Inc（REGN）の株式を保有している機関の数はいくつですか？
2025Q3時点で、Regeneron Pharmaceuticals Incの株式を保有している機関は2596社あり、保有株式の総市場価値は約94.26Mで、全体の91.26%を占めています。2025Q2と比較して、機関の持ち株は-4.43%増加しています。
Regeneron Pharmaceuticals Incの最大の収益源は何ですか？
FY2025Q2において、Sanofi部門がRegeneron Pharmaceuticals Incにとって最大の収益を生み出しており、その金額は1.44Bで、全収益の39.28%を占めています。
